New oral drug tested for aggressive blood cancer that has returned
Disease control
Completed
This study tested an experimental oral medication called AZD4205 in adults whose peripheral T-cell lymphoma, a type of blood cancer, had returned or did not respond to prior treatment. The main goal was to see if the drug could shrink tumors and how safe it was for patients. Rese…
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC